Clinical trials: Hepatocellular
Hepatocellular Carcinoma
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Researchers are looking for a better way to treat people diagnosed with liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment (advanced metastatic hepatocellular carcinoma…
- Trial name
- NCT04696055
- Testing
- Pembrolizumab, Regorafenib (Stivarga, BAY73-4506)
- Where
- 39 sites in United States, France and 6 more
- Volunteers
- 95 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
This is a Phase IIIb, one arm, multicenter, open-label study primarily designed to evaluate the safety of atezolizumab + bevacizumab in participants with unresectable or unsuitable for locoregional treatments for metastatic HCC…
- Trial name
- NCT04732286
- Testing
- Atezolizumab, Bevacizumab
- Where
- 25 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as…
- Trial name
- NCT02764801
- Testing
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
- Where
- 3 sites in United States
- Volunteers
- 131 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma.
- Trial name
- NCT01754987
- Testing
- Ascorbic Acid + Sorafenib, Sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Liver Tumor, Hepatocellular Carcinoma
NeuWave Microwave Ablation HCC China Study
This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the…
- Trial name
- NW (NCT03783871)
- Testing
- Microwave ablation
- Where
- 4 sites in China
- Volunteers
- 135 people
- Sponsor
- Ethicon, Inc.
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC.
- Trial name
- NCT02234986
- Testing
- ENMD-2076
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- CASI pharmaceuticals, Inc.
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Hepatocellular Carcinoma
Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
Cabozantinib, a small molecule directed to vascular endothelial growth factor receptors, MET and AXL, has shown to significantly improve the overall survival (OS) over placebo in the randomized phase 3 CELESTIAL trial in patients…
- Trial name
- ACTION (NCT04316182)
- Testing
- Cabozantinib
- Where
- 6 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
This trial studies how well stereotactic body radiation therapy works in treating patients with liver cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with…
- Trial name
- NCT03812289
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- OHSU Knight Cancer Institute
Primary Liver Carcinoma
Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Open label, single arm, multi-centre study of pembrolizumab following trans-arterial chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer (hepatocellular cancer; HCC) will be assessed.
- Trial name
- PETAL (NCT03397654)
- Testing
- Pembrolizumab, Trans-arterial chemoembolization
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Imperial College London
Hepatocellular Carcinoma
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
- Trial name
- NCT05233098
- Testing
- Technetium-99m macroaggregated albumin (Tc-99m MAA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Boston Scientific Corporation
Advanced Hepatocellular Carcinoma
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in…
- Trial name
- NCT04948697
- Testing
- Ociperlimab, Tislelizumab, BAT1706
- Where
- 28 sites in China, Taiwan
- Volunteers
- 94 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02576509
- Testing
- Nivolumab, Sorafenib
- Where
- 138 sites in United States, Australia and 20 more
- Volunteers
- 743 people
- Sponsor
- Bristol-Myers Squibb
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Hepatocellular Carcinoma
ABT-888 and Temozolomide for Liver Cancer
This study is for people with liver cancer (also called hepatocellular carcinoma, or HCC in abbreviation). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and temozolomide…
- Trial name
- NCT01205828
- Testing
- Temozolomide, ABT-888
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Georgetown University
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
This phase II trial studies the best dose and side effects of sorafenib tosylate and nivolumab in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to nearby tissues or lymph nodes…
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03439891
- Testing
- Nivolumab, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Robin Kate Kelley
Carcinoma, Carcinoma, Hepatocellular
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in…
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- MAApping (NCT05848947)
- Testing
- 99mTc-Macro Albumin Aggregate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing…
- Trial name
- NCT05776875
- Testing
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University